Okada N, Higashiyama M, Morimoto S, Yoshikawa K
Department of Dermatology, Osaka University School of Medicine.
Nihon Hifuka Gakkai Zasshi. 1991 Apr;101(5):547-52.
Radiographic skeletal examinations were performed in sixteen adult patients who had received etretinate therapy for various keratinizing disorders (psoriasis vulgaris 13, pustular psoriasis 2, pustulosis palmoplantaris 1) over periods ranging from 0.7 to 4.5 years. The total dose of etretinate ranged from 5.1 to 36.5 g. In these patients, the frequency and the degree of skeletal alterations including hyperostosis, calcification of ligaments and periosteal thickening was found to be higher than that in age- and -sex matched, nontreated controls. Furthermore, almost all of these patients were asymptomatic and revealed no abnormalities in laboratory data, including levels of serum calcium, inorganic phosphate and alkaline phosphatase. It is necessary for patients who are undergoing long-term etretinate therapy to be examined regularly for such skeletal abnormalities.
对16名成年患者进行了骨骼X线检查，这些患者因各种角化性疾病（寻常型银屑病13例、脓疱型银屑病2例、掌跖脓疱病1例）接受阿维A酯治疗，治疗时间为0.7至4.5年。阿维A酯的总剂量为5.1至36.5克。在这些患者中，发现包括骨质增生、韧带钙化和骨膜增厚在内的骨骼改变的频率和程度高于年龄和性别匹配的未治疗对照组。此外，几乎所有这些患者均无症状，实验室数据包括血清钙、无机磷和碱性磷酸酶水平均无异常。接受长期阿维A酯治疗的患者有必要定期检查是否存在此类骨骼异常。
